Comparative Pharmacology
Head-to-head clinical analysis: MOUNJARO versus WEGOVY HD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOUNJARO versus WEGOVY HD.
MOUNJARO vs WEGOVY HD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirzepatide is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It activates GIP and GLP-1 receptors, potentiating glucose-dependent insulin secretion from pancreatic beta cells, reducing glucagon secretion, slowing gastric emptying, and promoting satiety via hypothalamic appetite regulation.
WEGOVY (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety.
Subcutaneous injection once weekly. Starting dose: 2.5 mg for 4 weeks, then increase to 5 mg for at least 4 weeks. For additional glycemic control, may increase in 2.5 mg increments after at least 4 weeks on current dose. Maximum dose: 15 mg once weekly.
Subcutaneous injection once weekly. Initiate at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg weekly for 4 weeks, then 1 mg weekly for 4 weeks, then 1.7 mg weekly for 4 weeks, then maintain at 2.4 mg weekly.
None Documented
None Documented
Terminal elimination half-life is approximately 5 days (range 4-6 days), supporting once-weekly dosing. Achieves steady-state after 4-5 weeks.
Terminal elimination half-life approximately 165 hours (≈7 days), supporting once-weekly dosing.
Primarily eliminated via proteolytic degradation, with the parent drug not significantly excreted renally or in feces. Small amounts of metabolites may be excreted in urine and feces.
Primarily renal elimination of intact peptide; ~47% excreted unchanged in urine, remainder via fecal/biliary routes (≈38%).
Category C
Category C
Dual GIP/GLP-1 Receptor Agonist
GLP-1 Receptor Agonist